The development of novel anti-hyperlipidemic drugs: a tough business gets tougher.
Krause
Brian R
BR
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000037:antagonists & inhibitors; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004345:Drug Industry / Q000639:trends; D000069438:Ezetimibe; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009841:Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001384:Azetidines; D004338:Drug Combinations; D000960:Hypolipidemic Agents; D009841:Oligonucleotides; C524142:mipomersen; D000069438:Ezetimibe